Metformin And Pioglitazone Overview
Metformin/pioglitazone is a prescription medication used to treat type 2 diabetes. It is a single product containing 2 medications: pioglitazone and metformin. Pioglitazone belongs to a group of drugs called thiazolidinediones. These work by increasing the body’s sensitivity to insulin. Metformin belongs to a group of drugs called biguanides. These work by decreasing the amount of glucose absorbed from food and decreasing the amount of glucose that is produced by the liver. This medication comes in tablet form and is taken one or two times a day, with food. Common side effects of metformin/pioglitazone include upper respiratory tract infection, edema, diarrhea, headache, muscle pain, and weight gain. In combination with other medications to treat diabetes, metformin/pioglitazone can also cause hypoglycemia (low blood sugar), which can cause blurred vision and dizziness. Do not drive or operate heavy machinery until you know how metformin/pioglitazone affects you. Continue reading >>
Metformin-pioglitazone
Metformin and pioglitazone is a combination of two oral diabetes medicines that help control blood sugar levels. Metformin and pioglitazone is for people with type 2 diabetes who do not use daily insulin injections. This medication is not for treating type 1 diabetes. Metformin and pioglitazone may also be used for purposes not listed in this medication guide. You should not use this medicine if you have severe or uncontrolled heart failure, kidney problems, active bladder cancer, metabolic acidosis, or diabetic ketoacidosis (call your doctor for treatment with insulin). Metformin and pioglitazone is not for treating type 1 diabetes. Metformin and pioglitazone can cause or worsen congestive heart failure. Call your doctor at once if you have shortness of breath (even with mild exertion), swelling, or rapid weight gain. If you need to have any type of x-ray or CT scan using a dye that is injected into your veins, you will need to temporarily stop taking metformin and pioglitazone. Some people develop lactic acidosis while taking metformin. Get emergency medical help if you have even mild symptoms such as: muscle pain or weakness, numb or cold feeling in your arms and legs, trouble breathing, stomach pain, nausea with vomiting, slow or uneven heart rate, dizziness, or feeling very weak or tired. You should not use this medicine if you are allergic to metformin or pioglitazone, or if you have: diabetic ketoacidosis (call your doctor for treatment with insulin). If you need to have any type of x-ray or CT scan using a dye that is injected into your veins, you will need to temporarily stop taking metformin and pioglitazone. Be sure your caregivers know ahead of time that you are using this medication. Some people taking metformin develop a serious condition called lactic ac Continue reading >>
Actoplus Met New Fda Drug Approval | Centerwatch
ACTOplus met is a single dose combination of two approved drugs for the treatment of type 2 diabetes: Actos (pioglitazone) and metformin. Actos reduces insulin resistance and metformin lowers the amount of blood sugar made by the liver. ACTOplus met is specifically indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and metformin or who have inadequate glycemic control on a thiazolidinedione alone or metformin alone. ACTOplus met is supplied as a tablet for oral administration. The recommended initial dose is as follows: Starting dose for patients inadequately controlled on metformin monotherapy Based on the usual starting dose of pioglitazone (15-30 mg daily), ACTOplus met may be initiated at either the 15 mg/500 mg or 15 mg/850 mg tablet strength once or twice daily, and gradually titrated after assessing adequacy of therapeutic response. Starting dose for patients who initially responded to pioglitazone monotherapy and require additional glycemic control Based on the usual starting doses of metformin (500 mg twice daily or 850 mg daily), ACTOplus met may be initiated at either the 15 mg/500 mg twice daily or 15 mg/850 mg tablet strength once daily, and gradually titrated after assessing adequacy of therapeutic response. Starting dose for patients switching from combination therapy of pioglitazone plus metformin as separate tablets ACTOplus met may be initiated with either the 15 mg/500 mg or 15 mg/850 mg tablet strengths based on the dose of pioglitazone and metformin already being taken. At the time of FDA approval, no efficacy studies had been conducted with ActoPlus Met single tablets. However, efficacy and safety of the separate components had been previ Continue reading >>
Pioglitazone/metformin.
1. Drugs. 2006;66(14):1863-77; discussion 1878-80. (1)Wolters Kluwer Health, Adis, Auckland, New Zealand. [email protected] A fixed-dose pioglitazone/metformin tablet is approved in the US and the EU forthe treatment of adult patients with type 2 diabetes mellitus who currently have inadequate glycaemic control with metformin monotherapy. In the US, thecombination tablet is also approved for the treatment of adult patients with type2 diabetes who currently have inadequate glycaemic control with pioglitazonemonotherapy and for those already receiving a combination of pioglitazone andmetformin. Bioequivalence, based on absorption and bioavailability parameters,has been established between the fixed-dose tablets and equivalent doses ofpioglitazone and metformin coadministered as separate agents. Combination therapywith pioglitazone plus metformin was significantly more effective at improvingboth glycaemic and lipid control than metformin plus placebo in patients withtype 2 diabetes in a 16-week, well designed trial. Pioglitazone plus metformindemonstrated similar antihyperglycaemic efficacy to that of rosiglitazone plusmetformin in a well designed 12-month trial; however, pioglitazone plus metforminwas the superior combination in terms of lipid control. In several comparativetrials of 1-3.5 years' duration, pioglitazone plus metformin was at least aseffective as combination therapy with a sulphonylurea plus metformin in terms of antihyperglycaemic efficacy, but provided superior lipidaemic control with regardto levels of triglyceride and high-density lipoprotein-cholesterol. Pioglitazone plus metformin was generally well tolerated in patients with type 2 diabetes,with adverse events common to metformin monotherapy observed at a similarincidence to that with metformin plus Continue reading >>
Pioglitazone
Pioglitazone and other similar medications for diabetes may cause or worsen heart failure (condition in which the heart is unable to pump enough blood to the other parts of the body). Before you start to take pioglitazone, tell your doctor if you have or have ever had heart failure, especially if your heart failure is so severe that you must limit your activity and are only comfortable when you are at rest or you must remain in a chair or bed. Also tell your doctor if you were born with a heart defect, and if you have or have ever had swelling of the arms, hands, feet, ankles, or lower legs; heart disease; high cholesterol or fats in the blood; high blood pressure; coronary artery disease (narrowing of the blood vessels that supply blood to the heart); a heart attack; an irregular heartbeat; or sleep apnea. Your doctor may tell you not to take pioglitazone or may monitor you carefully during your treatment. If you develop heart failure, you may experience certain symptoms. Tell your doctor immediately if you have any of the following symptoms, especially when you first start taking pioglitazone or after your dose is increased: large weight gain in a short period of time; shortness of breath; swelling of the arms, hands, feet, ankles, or lower legs; swelling or pain in the stomach; waking up short of breath during the night; needing to sleep with extra pillows under your head in order to breathe easier while lying down; frequent dry cough or wheezing; difficulty thinking clearly or confusion; fast or racing heart beat; not able to walk or exercise as well; or increased tiredness. Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with pioglitazone and each time you refill your prescription. Rea Continue reading >>
Pioglitazone/metformin
Pioglitazone/metformin (also known by the brand names Actoplus Met, Piomet and Politor) is combination of two oral diabetes medications pioglitazone and metformin. The two oral antihyperglycemic agents with different mechanisms of action are used to improve glycemic control in patients with diabetes mellitus type 2. Mechanisms[edit] Pioglitazone is a member of the thiazolidinedione class, it decreases insulin resistance in the periphery and in the liver resulting in increased insulin dependent glucose disposal and decreased hepatic glucose output. Metformin is a member of the biguanide class, improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Indication[edit] Pioglitazone/metformin is indicated as an adjunct to diet and exercise: To improve glycemic control in patients with type 2 diabetes, or For patients who are already treated with a separate combination of pioglitazone and metformin, For patients whose diabetes is not adequately controlled with metformin alone, or For patients who have initially responded to pioglitazone alone and require additional glycemic control. Dosage and administration[edit] Recommended dose[edit] Use of antihyperglycemic agents in the management of type 2 diabetes should be individualized on the basis of effectiveness and tolerability. Pioglitazone/metformin should be given with meals; the initial starting dose is either the 15 mg/500 mg or 15 mg/850 mg tablet strength once or twice daily, and gradually titrated after assessing adequacy of therapeutic response, while not exceeding the maximum recommend Continue reading >>
Pioglitazone Hydrochloride Dosage. Online Drugstore No Rx
Pioglitazone Hydrochloride Dosage. Online Drugstore no RX Treating type 2 diabetes in certain patients. It is used along with diet and exercise. It may be used alone or with other antidiabetic medicines. Pioglitazone is a thiazolidinedione antidiabetic. It works by lowering blood sugar by making the cells of the body more sensitive to the action of insulin. Ginseng buy online buy american ginseng plants best ginseng seeds to buy where to buy american ginseng in los angeles buy panax ginseng australia. Ginseng root buyers ohio pioglitazone generic cost ginseng coffee buy pioglitazone 15 mg price buy ginseng tea online india buy high quality ginseng. Is pioglitazone a generic drug pioglitazone hydrochloride dose buy ginseng in nyc where can i buy korean ginseng tea. Price of pioglitazone buy american ginseng new york where to buy korean ginseng seeds pioglitazone metformin cost buy ginseng korea actos pioglitazone generic. Buy korean ginseng canada pioglitazone metformin cost pioglitazone hydrochloride drug bank buy ginseng in canada. Buy ginseng coffee bali generic form of buspar korean ginseng extract buy ginseng buyers in charleston wv pioglitazone combination drugs ginseng buyers in nj ginseng buyers in nova scotia. Where to buy ginseng seeds in ohio pioglitazone tabs pioglitazone price buy american ginseng los angeles where can i buy herbal viagra in leicester. Pioglitazone authorized generic where to buy korean ginseng tea in singapore generic brand for buspar where can i buy viagra over the counter in the uk. Ginseng buy australia where to buy ginseng seeds in canada ginseng buyers in franklin nc pioglitazone generic price pioglitazone metformin generic. Wild ginseng buyers in ny buy ginseng root uk pioglitazone generic alternative where can you buy herbal viagra. Continue reading >>
Actoplus Met (metformin Hydrochloride/pioglitazone) Dose, Indications, Adverse Effects, Interactions... From Pdr.net
Thiazolidinediones/Glitazone and Other Oral Antidiabetic Combinations Oral combination of metformin, a biguanide, and pioglitazone, a thiazolidinedione, for type 2 DM; rare but serious risk of lactic acidosis. Actoplus Met XR Oral Tab ER: 15-1000mg, 30-1000mg Actoplus Met/Pioglitazone Hydrochloride, Metformin Hydrochloride/Pioglitazone, Metformin Hydrochloride Oral Tab: 15-500mg, 15-850mg For the treatment of type 2 diabetes mellitus in combination with diet and exercise and when treatment with both metformin and pioglitazone is appropriate. NOTE: Metformin; pioglitazone is not for use in patients with type 1 diabetes or diabetic ketoacidosis. NOTE: When metformin; pioglitazone is used in combination with insulin or an insulin secretagogue, a lower dose of the insulin or insulin secretagogue may be needed in order to reduce the risk of hypoglycemia. In patients taking insulin and metformin; pioglitazone who experience hypoglycemia, reduce the dose of insulin by 10 to 25%. Individualize any further adjustments based on glycemic response. NOTE: When adding pioglitazone to metformin in patients with or without symptomatic heart disease and diabetes, monitor closely for signs of weight gain, peripheral edema, or congestive heart failure. In general, pioglitazone should be initiated at the lowest dose and increased gradually after at least three months of therapy. The risk of these symptoms is increased when higher doses of pioglitazone are used in combination with insulin in patients at risk of congestive heart failure. Pioglitazone should not be used in patients with New York Heart Association Class III or IV heart failure; metformin should not be used in patients with congestive heart failure requiring pharmacological therapy. Metformin; pioglitazone should be discontinu Continue reading >>
Pioglitazone And Metformin Fixed-dose Combination In Type 2 Diabetes Mellitus: An Evidence-based Review Of Its Place In Therapy
Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy We are experimenting with display styles that make it easier to read articles in PMC. The ePub format uses eBook readers, which have several "ease of reading" features already built in. The ePub format is best viewed in the iBooks reader. You may notice problems with the display of certain parts of an article in other eReaders. Generating an ePub file may take a long time, please be patient. Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy Giuseppe Derosa and Sibilla Anna Teresa Salvadeo Type 2 diabetes mellitus, a metabolic disease with increasing incidence, is one of the most important cardiovascular risk factors. Insulin resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Metformin and the thiazolidinediones, pioglitazone and rosiglitazone, are insulin-sensitizing agents available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of both metformin and pioglitazone in reducing cardiovascular morbidity and mortality. The fixed-dose combination of metformin and pioglitazone appears to be a good option for treating diabetes in insulin-resistant patients. The purpose of this article is to review the place in therapy of a fixed-dose combination of pioglitazone and metformin in the management of patients with type 2 diabetes. The current evidence suggests that combined therapy may help to achieve the recommended goals in the management of diabetes. A fixed-dose formulation of pioglitazone and metformin may provide advantages in terms of glycemic control and other cardiovascular risk factor Continue reading >>
- Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes
- Olive oil in the prevention and management of type 2 diabetes mellitus: a systematic review and meta-analysis of cohort studies and intervention trials
- Type 2 Diabetes: Mastering Injectable Combination Therapies to Individualize & Optimize Outcomes
Actoplus Met, Actoplus Met Xr Drug Imprint
(pioglitazone and metformin hydrochloride) Tablets CONGESTIVE HEART FAILURE AND LACTIC ACIDOSIS Thiazolidinediones, including pioglitazone, which is a component of ACTOPLUS MET, cause or exacerbate congestive heart failure in some patients [see WARNINGS AND PRECAUTIONS ]. After initiation of ACTOPLUS MET, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of ACTOPLUS MET must be considered [see WARNINGS AND PRECAUTIONS ]. ACTOPLUS MET is not recommended in patients with symptomatic heart failure. Initiation of ACTOPLUS MET in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated [see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS ]. Lactic acidosis is a rare but serious complication that can occur due to metformin accumulation. The risk increases with conditions such as sepsis, dehydration, excess alcohol intake, hepatic impairment, renal impairment, and acute congestive heart failure [see WARNINGS AND PRECAUTIONS ]. The onset is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and nonspecific abdominal distress. Laboratory abnormalities include low pH, increased anion gap, and elevated blood lactate [see WARNINGS AND PRECAUTIONS ]. If acidosis is suspected, ACTOPLUS MET should be discontinued and the patient hospitalized immediately [see WARNINGS AND PRECAUTIONS ]. ACTOPLUS MET tablets are a thiazolidinediones andbiguanide combination product that contains two oral antidiabetic medications:pioglitazone hydrochlori Continue reading >>
Actoplus Met (pioglitazone,metformin) Dosage, Indication, Interactions, Side Effects | Empr
Select the drug indication to add to your list Pioglitazone (as HCl), metformin HCl; 15mg/500mg, 15mg/850mg; tabs. Adjunct to diet and exercise to improve glycemic control in type 2 diabetes in patients already on pioglitazone and metformin, or when response to pioglitazone or metformin alone is inadequate. Give in divided doses with meals. Individualize. Previously on pioglitazone and/or metformin: switch on a mg/mg basis. Initially 15mg/500mg twice daily or 15mg/850mg once daily; may titrate gradually as needed; max 45mg pioglitazone/2550mg metformin per day. With CHF (NYHA Class I or II): initially 15mg/500mg or 15mg/850mg once daily. Concomitant strong CYP2C8 inhibitors: max 15mg/850mg daily. Renal impairment (eGFR 3045mL/min/1.73m2): not recommended. If eGFR <45mL/min/1.73m2, assess risk/benefit; discontinue if eGFR <30mL/min/1.73m2. NYHA Class III or IV heart failure. Severe renal impairment (eGFR <30mL/min/1.73m2). Metabolic acidosis. Diabetic ketoacidosis. Symptomatic HF: not recommended. Monitor for signs/symptoms of CHF; discontinue or reduce dose if occurs. Increased risk of metformin-associated lactic acidosis in renal or hepatic impairment, concomitant use of certain drugs (eg, cationic drugs), 65yrs of age, undergoing radiological contrast study, surgery and other procedures, hypoxic states, and excessive alcohol intake; discontinue if lactic acidosis occurs. Discontinue at time of, or prior to intravascular iodinated contrast imaging in patients with eGFR 3060mL/min/1.73m2, history of hepatic impairment, alcoholism, heart failure, or will be given intra-arterial contrast; reevaluate eGFR 48hrs after procedure and restart therapy if renally stable. Suspend therapy if dehydration occurs or before surgery. Avoid if clinical or lab evidence of hepatic diseas Continue reading >>
Pioglitazone Dosage :: Cheap Pills Online
Generic cialis levitra viagra | Propecia buy now | Cheapest fildena 100 | Generic drugstore online Treating type 2 diabetes in certain patients. It is used along with diet and exercise. It may be used alone or with other antidiabetic medicines. Pioglitazone is a thiazolidinedione antidiabetic. It works by lowering blood sugar by making the cells of the body more sensitive to the action of insulin. Best place to buy generic cialis online is xanax or valium better for flying pioglitazone vs metformin sildenafil hormosan rezeptfrei kaufen. Isoptin 80 mg tablets isoptin tablete forum buy clomid online next day delivery uk valium or xanax for nerves valium or xanax stronger. Rezeptfreies sildenafil cheap generic cialis online pioglitazone vs metformin pcos isoptin 120 mg retard filmtabletten. Pioglitazone generic cost generic viagra and cialis online what is stronger xanax valium or klonopin cialis online generic valium or klonopin stronger. Can i buy clomid online uk can buy clomid online pioglitazone metformin cost buy cialis generic online cheap valium or klonopin to sleep homeopathic drug stores in canada. Sildenafil rezeptfrei aus deutschland valium or xanax bluelight buy clomid online in the uk sildenafil hexal rezeptfrei pioglitazone tablets price. Pioglitazone 45 mg price pioglitazone vs glimepiride order cialis genericorder generic cialis online how much does prozac for cats cost. Medication called pioglitazone Buy fluconazole free delivery pioglitazone price uk isoptin sr 240 mg tablets sildenafil prparate rezeptfrei. Valium or xanax for insomnia pioglitazone hydrochloride price isoptin sr tablets pioglitazone class of medication Doxycycline for acne price . What is stronger 10mg valium or 1mg xanax pioglitazone 15 mg price isoptin 80 mg film tablet fiyat whats st Continue reading >>
Pioglitazone-metformin Extended-release Fixed-dose Combination For The Treatment Of Type 2 Diabetes
Background: Combination oral glucose-lowering drug therapy is often required to maintain glycemic control in patients with type 2 diabetes. Single-tablet fixed-dose combinations of oral glucose-lowering agents provide one means to increase adherence, which may improve metabolic and clinical outcomes. A new fixed-dose combination of pioglitazone and extended-release metformin has recently been approved in the US in dosage strengths of 15 mg/1000 mg and 30 mg/1000 mg. Aims: To review the clinical pharmacokinetics, efficacy and safety of the fixed-dose combination of pioglitazone and extended-release metformin, and to discuss the rationale behind its development. Data Sources: English-language articles from PubMed (without date restriction) using key words pioglitazone, metformin, extended- release and fixed-dose combination. Additional sources included published conference abstracts and US prescribing information. Results: The efficacy and safety/tolerability of pioglitazone and immediate-release metformin as dual therapy have been established in randomized controlled trials. This combination provides durable glycemic control over 2 years and is associated with a low risk of hypoglycemia. Individually, both drugs have evidence for macrovascular benefits. Potential drawbacks include weight gain and edema with pioglitazone and gastrointestinal disturbances with metformin. Published clinical data regarding the specific combination of pioglitazone and extended-release metformin (either as fixed-dose combination or dual therapy) remain scarce. However, bioequivalence between fixed-dose combination and dual therapy has been demonstrated, and studies have confirmed equivalence between extended-release metformin and immediate-release metformin in terms of drug exposure and effic Continue reading >>
- Type 2 Diabetes: Mastering Injectable Combination Therapies to Individualize & Optimize Outcomes
- Lilly's Trulicity (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes
- Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE)
A Fixed-dose Combination Of Pioglitazone And Metformin:a Promising Alternative In Metabolic Control
Get access/doi/pdf/10.1185/030079906X121002?needAccess=true Background: When type 2 diabetes is managed with glucose-lowering monotherapy, glycemic control ultimately deteriorates due to the inability of the -cell to overcome insulin resistance. Combining drugs with different complementary mechanisms of action improves long-term glycemic control and may lower the risk of vascular complications. A fixed-dose combination of pioglitazone (a thiazolidinedione) and metformin has been approved for use in the US (Actoplus met ) and in Europe (Competact ). Scope: This review (based upon MEDLINE and EMBASE searches from January 1990 to April 2006) discusses the potential benefits of co-formulating metformin and pioglitazone with respect to compliance and targeting glycemia, as well as other metabolic parameters. Findings: Pioglitazone increases insulin sensitivity, while metformin reduces hepatic gluconeogenesis and improves peripheral glucose uptake. Both agents reduce hyperglycemia and hyperinsulinemia, and appear to protect cell function. Their similar pharmacokinetic time profiles have facilitated a co-formulation bioequivalent to their separate administration. In randomized studies, pioglitazone and metformin administered separately provided significantly better glycemic control than metformin monotherapy or metformin plus gliclazide. Pioglitazone and metformin have complimentary benefits on diabetic dyslipidemia; pioglitazone primarily improves high-density lipoprotein cholesterol and triglyceride levels (to a greater extent than rosiglitazone does), while metformin mainly improves total cholesterol. Pioglitazone and metformin also modulate other atherosclerosis biomarkers, including inflammatory mediators, coagulation thrombosis components, and carotid intima media thick Continue reading >>
Pioglitazone-metformin
Nausea , vomiting , stomach upset, diarrhea , weakness , sore throat , muscle pain , weight gain, tooth problems or a metallic taste in the mouth may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly. If stomach symptoms return later (after taking the same dose for several days or weeks), tell your doctor right away. Stomach symptoms that occur after the first days of your treatment may be signs of lactic acidosis . Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects. Tell your doctor right away if you have any serious side effects, including: new/worsening vision problems (such as blurred vision ), bone fracture, reddish-colored urine, urgent need to urinate, pain while urinating. Pioglitazone may rarely cause liver disease. Tell your doctor right away if you develop symptoms of liver disease, including: dark urine, yellowing of eyes / skin , persistent nausea / vomiting , stomach/ abdominal pain . This medication usually does not cause low blood sugar ( hypoglycemia ). Low blood sugar may occur if this drug is prescribed with other diabetes medications (such as insulin or a sulfonylurea). Low blood sugar is more likely if you drink large amounts of alcohol, do unusually heavy exercise , or do not consume enough calories from food. To help prevent low blood sugar , eat meals on a regular schedule, and do not skip meals. Check with your doctor or pharmacist to find out what you should do if you miss a meal. Symptoms of low blood sugar include sudden sweating , shaking, fast heartbeat, hunger , blurred vision , dizziness , or tingling hands/feet. It is a good habit t Continue reading >>
